- Home
- KPTI vs DOMO Comparison
KPTI vs DOMO Comparison
Compare KPTI & DOMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPTI | DOMO |
|---|---|---|
| Founded | 2008 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.6M | 189.3M |
| IPO Year | 2013 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KPTI | DOMO |
|---|---|---|
| Price | $5.34 | $2.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $15.33 | $11.15 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 05-11-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $146,067,000.00 | ★ $317,044,000.00 |
| Revenue This Year | N/A | $3.38 |
| Revenue Next Year | $46.62 | $4.74 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 0.57 | N/A |
| 52 Week Low | $3.51 | $3.06 |
| 52 Week High | $10.99 | $18.49 |
Technical Indicators
Market Signals| Indicator | KPTI | DOMO |
|---|---|---|
| Relative Strength Index (RSI) | 29.62 | 31.90 |
| Support Level | $3.93 | N/A |
| Resistance Level | $6.82 | $5.39 |
| Average True Range (ATR) | 0.86 | 0.39 |
| MACD | -0.36 | -0.05 |
| Stochastic Oscillator | 9.41 | 2.82 |
Price Performance
Historical ComparisonAbout KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
About DOMO Domo Inc. Class B
Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.